Inj velmanase alfa-tycv 1 mg
Products billed under this code include Lamzede.
Payment limit per 1 MG, by effective quarter, 4Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Lamzede.
Payment limit per 1 MG, by effective quarter, 4Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Lamzede | Chiesi USA, Inc. | 10122-0180-02 | 10 | $4,791.91 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $479.191 | $0.00 | 1 MG | Inj velmanase alfa-tycv 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $479.191 | +$13.957 | 1 MG | Inj velmanase alfa-tycv 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $465.234 | $0.00 | 1 MG | Inj velmanase alfa-tycv 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $465.234 | $0.00 | 1 MG | Inj velmanase alfa-tycv 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $465.234 | +$0.185 | 1 MG | Inj velmanase alfa-tycv 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $465.049 | +$20.073 | 1 MG | Inj velmanase alfa-tycv 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $444.976 | +$4.168 | 1 MG | Inj velmanase alfa-tycv 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $440.808 | −$1.196 | 1 MG | Inj velmanase alfa-tycv 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $442.004 | – | 1 MG | Inj velmanase alfa-tycv 1 mg | v1, posted June 11, 2025 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.